Skip to main content
Erschienen in: Virchows Archiv 6/2004

01.12.2004 | Case Report

c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study

verfasst von: Katharina Pauls, Eva Wardelmann, Sabine Merkelbach-Bruse, Reinhard Büttner, Hui Zhou

Erschienen in: Virchows Archiv | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Dysgerminomas are rare female germ-cell tumors that correspond histologically and immunohistochemically to seminomas. Analogous to seminomas, most dysgerminomas respond very well to cisplatin- or carboplatin-based chemotherapy and to radiotherapy. KIT tyrosine kinase is crucial for normal germ-cell development, and its expression is observed in the majority of seminomas and dysgerminomas. Recently, activating KIT mutations were described in a panel of male germ-cell tumors [5, 10]. All mutations were localized in exon 17, encoding the second tyrosine kinase domain. Because receptor tyrosine kinase KIT might also be involved in the pathogenesis of dysgerminomas, we studied the expression and mutational status of a pure dysgerminoma, which was sent to our department for diagnostic reasons. The tumor revealed an exon 17 D816 V mutation in the c-KIT gene and strong KIT expression was found immunohistochemically. Clinically, the tumor was highly aggressive and resistant to carboplatin-based chemotherapy. Our case raises the question of whether exon 17 c-KIT mutations might be involved in the pathogenesis of dysgerminoma and whether exon 17 KIT mutations may predict aggressive and chemotherapy-resistant behavior of dysgerminomas.
Literatur
1.
Zurück zum Zitat Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-KIT mutation and response to imatinib. Blood 103:3222–3225CrossRefPubMed Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-KIT mutation and response to imatinib. Blood 103:3222–3225CrossRefPubMed
2.
Zurück zum Zitat Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I, Reilly J (1999) c-KIT proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105:894–900CrossRefPubMed Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I, Reilly J (1999) c-KIT proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105:894–900CrossRefPubMed
3.
Zurück zum Zitat Gershenson DM (1993) Update on malignant ovarian germ cell tumors. Cancer 71:1581–1590PubMed Gershenson DM (1993) Update on malignant ovarian germ cell tumors. Cancer 71:1581–1590PubMed
4.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed
5.
Zurück zum Zitat Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC (2004) KIT mutations are common in testicular seminomas. Am J Pathol 164:305–313PubMed Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC (2004) KIT mutations are common in testicular seminomas. Am J Pathol 164:305–313PubMed
6.
Zurück zum Zitat LaPolla JP, Benda J, Vigliotti AP, Anderson B (1987) Dysgerminoma of the ovary. Obstet Gynecol 69:859–864PubMed LaPolla JP, Benda J, Vigliotti AP, Anderson B (1987) Dysgerminoma of the ovary. Obstet Gynecol 69:859–864PubMed
7.
Zurück zum Zitat Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–1744CrossRefPubMed Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–1744CrossRefPubMed
8.
Zurück zum Zitat Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A (2003) Flt-3 and c-KIT mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:739–742 Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A (2003) Flt-3 and c-KIT mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:739–742
9.
Zurück zum Zitat Pauls K, Fink L, Franke FE (1999) Angiotensin-converting enzyme (CD143) in neoplastic germ cells. Lab Invest 79:1425–1435PubMed Pauls K, Fink L, Franke FE (1999) Angiotensin-converting enzyme (CD143) in neoplastic germ cells. Lab Invest 79:1425–1435PubMed
10.
Zurück zum Zitat Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K (2003) Alterations of the c-KIT gene in testicular germ cell tumors. Cancer Sci 94:486–491PubMed Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K (2003) Alterations of the c-KIT gene in testicular germ cell tumors. Cancer Sci 94:486–491PubMed
11.
Zurück zum Zitat Tatton L, Morley GM, Chopra R, Khwaja A (2003) The Src-selective kinase inhibitor PP1 also inhibits KIT and Bcr-Abl tyrosine kinases. J Biol Chem 278:4847–4853CrossRefPubMed Tatton L, Morley GM, Chopra R, Khwaja A (2003) The Src-selective kinase inhibitor PP1 also inhibits KIT and Bcr-Abl tyrosine kinases. J Biol Chem 278:4847–4853CrossRefPubMed
12.
Zurück zum Zitat Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD (1987) Current therapy for dysgerminoma of the ovary. Obstet Gynecol 70:268–275PubMed Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD (1987) Current therapy for dysgerminoma of the ovary. Obstet Gynecol 70:268–275PubMed
13.
Zurück zum Zitat Tian Q, Frierson HF JR, Krystal GW, Moskaluk CA (1999) Activating c-KIT gene mutations in human germ cell tumors. Am J Pathol 154:1643–1647PubMed Tian Q, Frierson HF JR, Krystal GW, Moskaluk CA (1999) Activating c-KIT gene mutations in human germ cell tumors. Am J Pathol 154:1643–1647PubMed
14.
Zurück zum Zitat Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer HP, Pfeifer U, Pietsch T (2002) c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15:125–136CrossRefPubMed Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer HP, Pfeifer U, Pietsch T (2002) c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15:125–136CrossRefPubMed
15.
Zurück zum Zitat Yan W, Suominen J, Toppari J (2000) Stem cell factor protects germ cells from apoptosis in vitro. J Cell Sci 113:161–168PubMed Yan W, Suominen J, Toppari J (2000) Stem cell factor protects germ cells from apoptosis in vitro. J Cell Sci 113:161–168PubMed
16.
Zurück zum Zitat Yoshinaga K, Nishikawa S, Ogawa M, Hayashi S, Kunisada T, Fujimoto T, Nishikawa S (1991) Role of c-KIT in mouse spermatogenesis: identification of spermatogonia as a specific site of c-KIT expression and function. Development 113:689–699PubMed Yoshinaga K, Nishikawa S, Ogawa M, Hayashi S, Kunisada T, Fujimoto T, Nishikawa S (1991) Role of c-KIT in mouse spermatogenesis: identification of spermatogonia as a specific site of c-KIT expression and function. Development 113:689–699PubMed
Metadaten
Titel
c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study
verfasst von
Katharina Pauls
Eva Wardelmann
Sabine Merkelbach-Bruse
Reinhard Büttner
Hui Zhou
Publikationsdatum
01.12.2004
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 6/2004
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-004-1112-3

Weitere Artikel der Ausgabe 6/2004

Virchows Archiv 6/2004 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …